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Abstract
Background: Sickle cell anaemia (SCA) is associated with growth failure. However, recent reports indicate high
rates of overweight or obesity among children with SCA in developed countries. It is unclear whether overweight
or obesity is also common in children with SCA in developing countries. The objectives of the study were to
determine the prevalence of overweight or obesity, wasting and stunting and identify predictors of wasting and
stunting among children with SCA in Nigeria.
Method: Children with SCA attending a public-funded tertiary hospital clinic were studied. Weight, height,
haemoglobin, haemoglobin fractions and white cell count were measured. Anthropometric values were converted
to z scores and referenced to the WHO Child Growth Standards and WHO Reference 2007. The proportions with
wasting, stunting and overweight or obesity were determined. Regression analysis was used to identify the
predictors of wasting and stunting.
Results: Two hundred and thirty-three children [mean (±SD) age of 9.0 (±4.0) years, 60.9 % males] participated in
the study. Wasting, stunting and overweight or obesity rates were 22.7 %, 11.6 % and 1.7 %, respectively. Boys and
children from low socioeconomic class were 3.25 (1.45-7.29) and 2.42 (1.14-5.18) times more likely to be wasted
respectively, while both wasting and stunting were more common with increasing age [adjusted OR of 1.33 (1.18-1.51)
and 1.15 (1.01-1.32) respectively]. Sickle cell-related complications and intake of oral penicillin and hydroxyurea were
not associated with wasting and stunting.
Conclusion: Overweight or obesity is uncommon while wasting and stunting are still prevalent in children with SCA in
Lagos. The strongest predictors of wasting and stunting were older age, male gender and low socioeconomic status.
Keywords: Obesity, Overweight, Sickle cell anaemia, Stunting, Wasting
Background
Sickle cell disease (SCD) is traditionally associated with
growth failure and delayed puberty [1, 2]. Among the SCD
genotypes, children with sickle cell anaemia (SCA) and
HB Sβ0 thalassemia have the most severe impairment in
growth [2, 3]. Similar to the general population, growth
failure in SCD has been associated with adverse events in-
cluding higher hospitalisation rate [4]. With improved
care children with SCD are living longer compared to life
expectancy several decades ago [5, 6]. The improvement
in the survival rate and overall health of children with
SCD has been attributed in part to early diagnosis of SCD,
penicillin prophylaxis, immunisation, stroke prevention,
administration of hydroxyurea and chronic blood transfu-
sion [5–8]. Reports from developing countries indicate
that these measures are also being increasingly used in the
population with SCD [9, 10]. Together, these measures
have resulted in better growth of children with SCD.
Indeed, recent studies from developed countries like the
USA indicate that overweight and obesity, together with
its complications such as hypertension and sleep apnoea
are becoming a health concern among children and ado-
lescents with SCD [11, 12]. One small study involving
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children less than six years with SCD in Nigeria, a devel-
oping country, has reported a similar pattern of over-
weight and obesity, in keeping with the trend in developed
countries [13]. In contrast, another small study in Lagos
involving children and adolescents with SCA reported a
2.5 % prevalence rate of obesity [14].
Although recent reports from developed countries indi-
cate that overweight and obesity are becoming prevalent in
the population with SCD it is unclear whether this trend is
emerging or established in children with SCD in developing
regions of the world. In the present study we determined
the prevalence of wasting, overweight or obesity and stunt-
ing among children and adolescents with SCA and identi-
fied factors including demographic, sickle cell-related
complications and interventions that may be associated
with wasting and stunting.
Methods
The study was conducted in the Paediatric Haematology
Clinic of the Lagos University Teaching Hospital be-
tween October 2014 and September 2015. It is a part of
a larger study aimed at determining the prevalence and
genetic risk of sickle cell nephropathy. All consecutive
children with SCA aged between 2 and 17 years were in-
cluded. Children were excluded if they were acutely ill
with fever or vaso-occlusive crisis or needed immediate
hospitalisation for other therapeutic purposes, had other
chronic illnesses not related to SCD or had received
blood transfusion in the three months preceding enrol-
ment in the study. These children were excluded in
order to have a study sample with hematologic parame-
ters as close as possible to baseline values. The medical
chart of each child was reviewed and the parents ques-
tioned about the age at diagnosis, history of sickle cell-
related complications such as stroke, chronic leg ulcers,
avascular necrosis of the hip, priapism, kidney disease
and acute chest syndrome. The number of times each
child had been hospitalised in the prior 12 months for
any illness or bone pains was also documented. Other
information of interests included the receipt of blood
transfusion ever and in the prior 12 months and the
daily use of oral penicillin and hydroxyurea.
Each child was examined with specific emphasis on
height and weight. The weight and height were mea-
sured by one of two investigators using a seca™ weighing
scale. The weight was measured to the nearest 50 g with
the child wearing light clothing while the height was
measured to the nearest 0.1 cm using a seca™ Leicester
floor mounted stadiometer. For height measurement the
child stood barefooted, erect with the occiput, shoulder
blades, buttocks, calf and heel making contact with the
stadiometer and the head in the Frankfurt plane. The
seca™ weighing scale was calibrated each study day with
known weights. Three millilitre of blood was obtained
aseptically from each child and analysed in the labora-
tory for complete blood count (using automated haema-
tology analyser) and haemoglobin fractions using
automated D-10™ Bio-rad high performance liquid chro-
matography system. Only children with sickle cell an-
aemia were included in this analysis because of the small
proportions with other sickle cell syndromes. Socioeco-
nomic status of the family of each child was determined
using the method described by Olusanya et al. [15]
which utilises the father’s occupation and mother’s high-
est education.
Statement of ethics and informed consent
The study obtained ethical approval from the Lagos
University Teaching Hospital’s Health Research Ethics
Committee before the commencement of the study. In
addition all caregivers of children included in the study
provided written informed consent. Assent was also
obtained from children 7 years or older.
Data analysis
Analysis of the study data was performed using IBM
SPSS Statistics version 21 (IBM Corp, Armonk, New
York, USA). In addition anthropometric variables of
each child were converted to z scores and referenced
to the WHO Child Growth Standards and WHO Ref-
erence 2007 using the WHO Anthroplus software
[16]. Weight for age z score was not computed for
children 10 years or older because the WHO Refer-
ence 2007 did not provide standards for this age
group. Using this reference, children with height for
age z (HAZ) score < -3, <-2 to -3, -2 to +3 and > +3
were classified as severe stunting, stunting, normal
and very tall, respectively, while BMI for age z (BMI
z) score < -3,-3 to < -2, -2 to +2, > + 2 to +3 and > +3
referred to severe wasting, wasting, normal, over-
weight and obese, respectively [17].
Univariate and multivariate analyses for factors associ-
ated with wasting and stunting were performed includ-
ing factors that have been reported in the literature to
be associated with nutritional status in the general and
sickle cell population. The factors included simultan-
eously as independent variables in the multiple logistic
models were age, age at diagnosis of SCA, gender,
socioeconomic status, presence of sickle cell-related
complications, hospitalisation in the previous year, haemo-
globin level, percent foetal haemoglobin, white cell count
and use of oral penicillin and hydroxyurea. Categorical
variables such as gender, use of oral penicillin, obesity,
wasting were presented as proportions. Normally distrib-
uted data were presented as mean (±standard deviations)
while skewed data were summarised as median (range).
All analysis was two-tailed and p value <0.05 was consid-
ered statistically significant.
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Results
Two hundred and thirty-three (233) children with SCA
were included in the study. The mean age was 9.0 years
and 60.9 % were males. In the previous one year before
the study 33.5 % (n = 78) were hospitalised at least once
for some illnesses and 23.1 % (n = 54) for bone pain. Ex-
cept for acute chest syndromes, small proportions (<3 %
each) of the study participants had experienced sickle
cell-related complications such as stroke, leg ulcers or
avascular necrosis of the hip. About a quarter of the
children were receiving hydroxyurea and oral penicillin
each. All the nine children on chronic transfusion re-
ceived blood transfusions for only six months, the last
transfusion being at least three months before participa-
tion in the study; they were also receiving hydroxyurea.
About half had never received a blood transfusion
(Table 1). The mean HAZ and BMI z scores were -0.59
and -1.13 respectively.
Of the children studied, 27 (11.6 %) were either
stunted or severely stunted while 75.5 % children had
normal HAZ score. Wasting/severe wasting was ob-
served in 22.7 % of the sample studied; 1.7 % children
were either overweighed or obese (Fig. 1).
Factors associated with wasting
Children with wasting/severe wasting were shorter than
children with normal weight (-1.31 versus -0.38). In
addition, the demographics of the children with wasting/
severe wasting were different from those with normal
weight; they were older, predominantly males (75.5 %)
and more likely to come from families with low socio-
economic status than children with normal weight. They
were also more likely to be diagnosed with SCA at a
later age than children with normal weight (Table 2 and
Fig. 2).
However, markers of severity of sickle cell anaemia
such as the presence of one or more SCA-related com-
plications such as acute chest syndrome, leg ulcers,
stroke, priapism and avascular necrosis of the hip were
similar in both. Also, the hospitalisation rate in the pre-
vious one year before the study and the haemoglobin
level were similar. In contrast, children with wasting had
significantly lower foetal haemoglobin percent than chil-
dren with normal weight (6.4 % versus 8.5 %). While the
proportion receiving hydroxyurea or chronic blood
transfusion was not different, significantly fewer children
with wasting were receiving daily oral penicillin (7.5 % v
26.7 %).
Factors associated with stunting
In addition to being stunted children with stunting had
lower BMI z score than those with normal height. Simi-
lar to wasting children with stunting were older than
children with normal HAZ score (11.2 versus 8.7 years)




Male, n % 142 (60.9)
Age, mean (SD), years 9.0 (4.0)
Adolescents (10-17 years), n % 98 (42.1)
Socio-economic class of family
High, n (%) 3 (1.3)
Middle, n (%) 138 (59.2)
Low, n (%) 92 (39.5)
Severity of sickle cell anaemia











Blood transfusion ever, n (%) 118 (50.6)
Blood transfusion previous year, n (%) 41 (17.6)
Acute chest syndrome, n (%) 33 (14.2)
Hip avascular necrosis, n (%) 6 (2.6)
Leg ulcers, n (%) 6 (2.6)
Stroke, n (%) 5 (2.1)
Priapism, n (%) 14 (9.9)b
Haemoglobin level, mean (SD), g/dL 8.4 (1.2)
Foetal haemoglobin, median (range), % 8.0 (1.0-28.6)
Interventions (current receipt)
Chronic transfusion, n (%) 9 (3.9)c
Hydroxyurea, n (%) 59 (25.3)
Daily oral penicillin, n (%) 52 (22.3)
Anthropometry
Weight, kg 25.8 (10.3)
Height, m 1.28 (0.21)
Body mass index, kg/m2 14.8 (2.07)
Height for age z score −0.59 (1.32)
Body mass index z score −1.13 (1.30)
asevere bone pain crisis was one requiring hospitalisation for more
than 24 hours
bpercentage of only male children; cthese children last received blood
transfusion at least 3 months before study participation; these children were
also taking hydroxyurea
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and had lower foetal haemoglobin percent (5.7 % versus
8.2 %). However, no other demographic variables or fea-
tures related to sickle cell anaemia were associated with
stunting, though children with stunting had higher white
cell count and were less likely to be receiving hydroxyurea.
In multiple logistic regressions (Table 3), only age was
a consistent predictor of both wasting and stunting in
the present study; with increasing age the likelihood of
wasting and stunting was higher (adjusted OR of 1.33
and 1.15, respectively). The strongest predictor of wast-
ing was the male gender (adjusted OR of 3.25) followed
by lower socioeconomic status (adjusted OR 2.42). On
the other hand stunting was independently predicted by
age and peripheral blood white cell count. Other
markers of severity of SCA or interventions such as the
use of oral penicillin or hydroxyurea were not signifi-
cantly associated with either stunting or wasting.
Discussion
The present study was premised on the increasing preva-
lence of overweight and obesity in the general population
of children globally and newer reports describing similar
trend in children with sickle cell disease, a condition pre-
viously associated with significant growth failure. In the
present study, we observed that wasting and stunting are
still prevalent among children with SCA in a developing
country like Nigeria, while overweight and obesity are
uncommon. Other recent studies from developing coun-
tries have reported similar findings. For example, in 2012,
Cox et al. [4] in Tanzania reported that 15 % of a cohort
of children and adults with SCA had wasting or severe
wasting while a higher percentage had stunting. Although
a recent study in south east Nigeria reported higher rates
of overweight and obesity, suggesting that overweight and
obesity might be prevalent among children with SCD in
developing countries, reclassifying the study sample using
standard BMI z score of >2 and >3 for overweight and
obesity respectively resulted in only 3.4 % of the study
population being overweighed or obese [13]. Another re-
cent study in Lagos reported an obesity rate of 2.5 %
among 1-15 year old with SCA [14]. Together with the
current study, these reports indicate that overweight and
obesity are uncommon among children with SCD in de-
veloping countries such as Nigeria. Undernutrition rates
higher than the findings of the present study have also
been documented in children with SCA within the past
decade. For example, Al-Saqladi [18] observed that 35 %
and 54 % of a cohort of children with SCD less than
15 years were wasted and stunted respectively. The high
prevalence of wasting and stunting in the present study
despite increasing coverage of SCD-related health main-
tenance therapies is worrisome. In addition, the low per-
centages of children in the present study who had
experienced sickle-related complications and the low hos-
pitalisation rates for bone pain crisis or any illness in the
previous one year would suggest a not too severe SCA
phenotype, yet wasting and stunting were common.
In sharp contrast, reports from developed countries
paint an increasing problem of overweight and obesity
among the population with SCD. Recently, Chawla et al.
[11] observed overweight or obesity in over 20 % of
children with SCD in the USA. In that study the per-
centage of children with underweight was a third of the
overweight or obesity rate. Another study in the USA re-
ported similar findings; among 6-18 year olds with SCD
16-26 % had overweight or obesity using Centre for Dis-
ease Control reference values [12]. The increasing preva-
lence of overweight and obesity, two conditions with
significant adverse health impact, among children with
SCD in developed countries has mirrored the availability
of effective SCD-related interventions in these regions of
the world. Specifically, children with SCD in developed
countries are more likely to be diagnosed in early in-
fancy and started on pneumococcal prophylaxis, hy-
droxyurea and chronic transfusion than children in
developing countries like Nigeria [5, 9]. These interven-
tions have been associated with fewer infections, stroke,
hospitalisation rates and higher haemoglobin level [6–8].
For instance the steady state haemoglobin reported in the
study by Chawla [11] in the US was 9.5 g/dL compared
with 8.4 g/dL in the present study and 7.3–8.3 g/dL in a
Fig. 1 Nutritional status of children with sickle cell anaemia
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study in Yemen which reported higher rate of wasting and
stunting [18]. As observed in many studies, higher
haemoglobin is associated with better nutritional status
[11, 19, 20]. The higher prevalence of undernutrition in
the studies from developing countries especially those
in Africa may also be due to inclusion of only those with
SCA anaemia in the studies. Compared to the other
haemoglobin genotypes SCA is the most severe form of
SCD [2, 11].
Both stunting and wasting occur together in children
with sickle disease underlining the chronicity of SCD
and the frequent exacerbations of symptoms. In the
present study children with wasting were shorter than
children with normal weight while those with stunting
were more likely to be wasted than children with normal
height. In addition, consistent with other studies, weight
was more affected than height [21, 22]. Stunting and
wasting in SCD is attributed to higher resting energy
expenditure [23], repeated infections [24], endocrine
dysfunction [25], micronutrient deficiency [26] and
chronic anaemia [4, 11, 19]. The chronic nature of SCD
means that after birth and with increasing age stunting
and wasting become more common. Our finding sup-
ports this pattern of undernutrition as both stunting and
wasting were more common among the adolescents and
got severe with increasing age. Indeed only age was a
strong predictor of both wasting and stunting in the
present study. This association has been reported by sev-
eral other investigators in both developing and devel-
oped countries and in studies involving both children
and adults [4, 11]. It has been shown that with increas-
ing age energy intake becomes inadequate in children
with SCD [27].
The present study and published literature identify the
male children with SCA as the subgroup most affected
by growth impairment. In the present study the males
were three times more likely to be wasted than girls.
Chawla [11] and Mitchell [12] in the USA and Cox [4]
Table 2 Factors associated with wasting and stunting in children with sickle cell anaemia
Characteristics Wasting Stunting
Wasted/severely









Weight, mean (SD), kg 28.5 (8.9) 25.0 (10.5) 0.03 24.9 (9.4) 25.9 (10.4) 0.632
Height, mean (SD), m 1.41 (0.17) 1.24 (0.21) <0.01 1.27 (0.25) 1.28 (0.20) 0.752
BMI, mean (SD), kg/m2 13.89 (1.41) 15.50 (2.09) <0.001 15.00 (1.71) 15.15 (2.11) 0.700
Weight for age z scorea, mean (SD) −1.98 (0.87) −0.51 (1.04) <0.001 −2.04 (1.10) −0.58 (1.06) <0.001
Height for age z score, mean (SD) −1.31 (1.23) −0.38 (1.28) <0.001 −2.79 (0.68) −0.30 (1.10) <0.001
BMI for age z score, mean (SD) −2.82 (0.65) −0.63 (0.98) <0.001 −1.86 (1.61) −1.03 (1.22) 0.002
Demographics
Age, mean (SD), year 12.2 (3.7) 8.1 (3.6) <0.001 11.2 (5.0) 8.7 (3.8) 0.002
Adolescent, n (%) 38 (71.7) 60 (33.3) <0.001 18 (66.7) 80 (38.8) 0.006
Age at diagnosis of SCA, median(range) year 2.00 (0-14.0) 1.8 (0-12.0) 0.046 2.0 (0.0-12.0) 2.0 (0.0-14.0) 0.310
Male, n (%) 40 (75.5) 102 (56.7) 0.014 16 (59.3) 126 (61.2) 0.849
Low socioeconomic status, n (%) 31 (58.5) 61 (33.9) 0.001 13 (48.1) 79 (38.3) 0.327
SCA-related features
≥1 SCA-related complicationb, n (%) 15 (28.3) 39 (21.7) 0.314 6 (22.2) 48 (23.3) 0.901
Severe bone pain, previous year, n (%) 12 (22.6) 42 (23.2) 0.916 5 (18.5) 49 (23.8) 0.542
Hospitalisations, previous year, n (%) 16 (30.2) 62 (34.4) 0.564 8 (29.6) 70 (34.0) 0.652
Blood transfusion, ever, n (%) 33 (62.3) 85 (47.2) 0.054 15 (55.6) 103 (50.0) 0.587
Haemoglobin level, mean (SD), g/dL 8.3 (1.6) 8.4 (1.1) 0.927 8.4 (2.1) 8.4 (1.1) 0.764
Foetal haemoglobin level, (range), % 6.4 (1.4-19.1) 8.5 (1.0-28.6) 0.035 5.7 (1.3-15.8) 8.2 (1.0-28.6) 0.014
Total white cell count, x103/ml 12.9 (4.2) 13.8 (4.7) 0.212 15.2 (6.5) 13.4 (4.3) 0.051
SCA-related interventions
Daily oral penicillin intake, n (%) 4 (7.5) 48 (26.7) 0.003 3 (11.1) 49 (23.8) 0.137
Hydroxyurea or chronic transfusion, n (%) 9 (17.0) 50 (27.8) 0.112 3 (11.1) 56 (27.2) 0.071
aweight for age z score presented for 135 children younger than 10 years
bany of leg ulcer, acute chest syndrome, stroke, avascular necrosis of the hip, priapism or kidney disease
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Fig. 2 Age and gender-related decline in BMI for age and height for age z scores in children with sickle cell anaemia.
Table 3 Independent predictors of wasting and stunting in children with sickle cell anaemia
Predictors Wasting (BMI z score < -2) Stunting (HAZ score < -2)
Adjusted odds ratio (95 % CI) P value Adjusted odds (95 % CI) P value
Age 1.33 (1.18–1.51) <0.001 1.15 (1.01–1.32) 0.036
Male (versus female) 3.25 (1.45–7.29) 0.004 0.80 (0.33–1.97) 0.629
Low SESa (versus middle & high) 2.42 (1.14–5.18) 0.022 1.23 (0.50–3.03) 0.653
Age at diagnosis of SCA 1.00 (0.87–1.15) 0.990 1.12 (0.954–1.31) 0.167
Presence of ≥1 SCA–related complication 0.81 (0.33–1.96) 0.638 0.70 (0.24–2.08) 0.525
Previous year hospitalisation 0.76 (0.33–1.74) 0.514 0.70 (0.26–1.89) 0.586
Haemoglobin level 1.01 (0.75–1.35) 0.968 1.21 (0.87–1.67) 0.258
Foetal haemoglobin 0.99 (0.90–1.08) 0.767 0.91 (0.80–1.03) 0.116
Peripheral white cell count 0.98 (0.90–1.08) 0.680 1.16 (1.04–1.28) 0.007
Daily oral penicillin use 0.61 (0.18–2.07) 0.423 0.78 (0.19–3.16) 0.723
Hydroxyurea or chronic transfusion 0.54 (0.21–1.37) 0.197 0.50 (0.13–1.86) 0.300
aSES socioeconomic status
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in Tanzania separately documented that underweight or
wasting was more frequent among males than females.
The higher resting energy expenditure in boys compared
to girls and the increased likelihood of males to be in-
volved in outdoor physical activities may explain this
finding [28]. In addition, higher background inflamma-
tion and erythroid hyperactivity have been suggested as
other reasons for the higher rate of undernutrition in
male children with SCD [18]. The consistency of this ob-
servation in several studies identifies males with SCD as
a group requiring additional nutritional intervention
such as increased daily calorie intake. Furthermore, mea-
sures such as chronic blood transfusion may have bene-
ficial effect as they lower erythroid hyperactivity and
resting energy requirement [29].
Not unexpectedly, in the present study and others chil-
dren belonging to families with lower socioeconomic class
were more likely to be wasted [19, 30]. Higher socioeco-
nomic class implies better access to healthcare and better
nutrition, more so in developing countries where health-
care spending is usually out of pocket. For example, Wolf
et al. [19] observed that children with SCD whose family
head had higher education had higher weight and height,
while Zemel et al. [31] documented higher BMI z scores
in girls whose mothers had high educational level. It is
therefore conceivable that the rate of wasting and stunting
may be higher in children with SCA in rural regions of
Nigeria than the values obtained in the present study.
Our study suggests that in low-resource countries nutri-
tional status of children with SCA is still heavily influ-
enced by variables such as age, gender and socioeconomic
status and not necessarily by the factors related to severity
of SCA or its management. We did not find any associ-
ation between nutritional status and markers of severity of
SCA such as sickle-related complications, hospitalisation
and bone pain rates in the previous year and haemoglobin
level. Similarly, sickle cell-related interventions such as
daily oral penicillin and hydroxyurea were only weakly
protective against wasting and stunting in the present
study. Although several studies have observed lower
haemoglobin level in children with SCD and poorer nutri-
tional status the association with nutritional status has not
been consistently reported in the literature [11, 31, 32].
For example a study involving children in Yemen did not
find any association between nutritional status and
markers of severity of SCA [18]. Similarly, the impact of
hydroxyurea therapy on growth status has not been con-
sistent [33, 34]. Specific to the present study, the weak as-
sociation between use of hydroxyurea and nutritional
status may be due to the practice in the study centre to
commence hydroxyurea only in children with or at risk of
severe manifestations such as stroke and priapism. The as-
sociation between stunting and higher peripheral blood
white cell count has been previously reported [33]. It is
thought that the higher white cell count may underline
the ongoing chronic inflammation in sickle cell disease
which may impair growth [33]. However, we do not know
any reason why it was only associated with stunting but
not wasting in the present study.
Limitations
A major limitation of the present study was the reliance
on self-reports for hospitalisation rates and most compli-
cations of sickle cell disease. This is partly because chil-
dren with chronic disease such SCD in developing
countries also receive care in smaller, usually private
hospitals and these events are not adequately captured
in the medical charts in the tertiary hospital. Another
limitation was our inability to comment on the effect of
chronic blood transfusion on nutritional status in the
present study because only very few children included in
this study received the therapy. Although higher white
cell count in the blood suggests inflammation, apart
from excluding children with febrile illness or acute
complications of SCD we did not measure other sensi-
tive markers of inflammation such as C reactive protein,
erythrocyte sedimentation rate and serum transferrin
Conclusion
In a cohort of children with SCA attending an urban
public-funded tertiary hospital in Lagos, Nigeria, over-
weight or obesity was uncommon. Instead about 1 in 10
and 1 in 5 children with SCA had stunting and wasting re-
spectively. Stunting and wasting were more common and
severe in males and adolescents. However, sickle-cell re-
lated factors such as hospitalisation rates, history of com-
plications and use of oral penicillin and hydroxyurea were
not associated with wasting or stunting in these children.
Abbreviation
BMI z score: Body mass index for age z score; HAZ score: Height for age z
score; SCA: Sickle cell anaemia; SCD: Sickle cell disease; SD: Standard
deviation.
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